Bicalutamide: Difference between revisions
No edit summary |
No edit summary |
||
| Line 12: | Line 12: | ||
For future research, it will be useful to understand the precise mechanism of action of antiandrogens currently used in the clinic, with the objective of developing new drugs which can escape from the antagonist-agonist switch seen in bicalutamide or flutamide. One example of this is apalutamide, a non-steroidal second generation antiandrogen <ref name="ARA prostate" /><ref name="Role of AR">PMID: 30209899</ref>, approved for use in non metastatic castration resistant prostate cancer patients by the FDA in 2018 <ref name="Role of AR" />. See also the [https://clinicaltrials.gov/ct2/show/NCT01946204 SPARTAN study]<ref>PMID: 29420164</ref>. This new drug has promising uses but it is still associated with side effects like an increased level of falls in patients with the treatment vs placebo <ref>PMID: 36209239</ref>. | For future research, it will be useful to understand the precise mechanism of action of antiandrogens currently used in the clinic, with the objective of developing new drugs which can escape from the antagonist-agonist switch seen in bicalutamide or flutamide. One example of this is apalutamide, a non-steroidal second generation antiandrogen <ref name="ARA prostate" /><ref name="Role of AR">PMID: 30209899</ref>, approved for use in non metastatic castration resistant prostate cancer patients by the FDA in 2018 <ref name="Role of AR" />. See also the [https://clinicaltrials.gov/ct2/show/NCT01946204 SPARTAN study]<ref>PMID: 29420164</ref>. This new drug has promising uses but it is still associated with side effects like an increased level of falls in patients with the treatment vs placebo <ref>PMID: 36209239</ref>. | ||
[[1z95]]. | |||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||